Table 1.
Demographics of patients with CNV and controls ar baseline
| Eyes with CNV (n = 72) | Controls (n = 30) |
P** | |||||
|---|---|---|---|---|---|---|---|
| PNV (n = 22) |
PCV (n = 25) |
DA nAMD (n = 25) |
P* | All eyes with CNV (n = 72) |
|||
| Age, median (IQR) (year) |
72.0 (63.8–76.3) |
72.0 (66.5–77.5) |
77.0 (69.0–82.0) |
0.054 |
73.0 (68.0–78.0) |
69.0 (67.0–74.5) |
0.118 |
| Female, sex, n (%) |
4 (18.2) |
6 (24.0) |
10 (40.0) |
0.218 |
20 (27.8) |
17 (56.7) |
0.006 |
| LogMAR, median (IQR) |
0.22 (0.05–0.43) |
0.22 (0.10–0.35) |
0.22 (0.15–0.70) |
0.212 |
0.22 (0.10–0.52) |
0.35 (0.22–0.57) |
0.020 |
| Axial length, median (IQR) (D) |
23.58 (23.04–23.88) |
23.55 (22.91–24.25) |
23.51 (22.93–24.21) |
0.902 |
23.57 (22.97–24.18) |
24.04 (23.36–24.38) |
0.040 |
| Spherical equivalent, median (IQR) (D) |
0.50 (− 0.63 to 2.50) |
0.25 (− 1.44 to 1.31) |
− 0.63 (− 2.13 to 1.25) |
0.166 |
0.00 (− 1.36 to 1.44) |
− 0.31 (− 2.47 to 0.25) |
0.050 |
| CRT, median (IQR) (μm) |
404 (213–551) |
392 (271–510) |
422 (348–575) |
0.349 |
402 (288–548) |
– | – |
| SFCT, median (IQR) (μm) |
344 (261–415) |
268 (191–356) |
182 (107–252) |
< 0.001 |
260 (170–358) |
– | – |
| GLD, median (IQR) (μm) |
3.96 (2.92–6.29) |
3.89 (3.52–6.05) |
4.55 (2.69–6.58) |
0.916 |
4.19 (3.09–6.24) |
– | – |
| CNV size, median (IQR) (mm2) |
1.50 (0.90–4.09) |
1.06 (0.64–1.22) |
1.27 (0.39–2.70) |
0.146 |
1.18 (0.66–2.15) |
– | – |
| SRF, n (%) |
19 (86.4) |
24 (96.0) |
18 (72.0) |
0.060 |
61 (84.7) |
– | – |
| IRF, n (%) |
4 (18.2) |
5 (20.0) |
9 (36.0) |
0.288 |
18 (25.0) |
– | – |
| Soft drusen, n (%) |
0 (0) |
0 (0) |
16 (64.0) | < 0.001 |
16 (22.2) |
– | – |
| Pigmentary abnormality, n (%) |
12 (80.0) |
17 (89.5) |
15 (75.0) |
0.501 |
44 (81.5) |
||
The Kruskal–Wallis test was used for comparisons between three categories. The Mann–Whitney U test was used for comparisons between all eyes with CNV patients and controls.
nAMD, neovascular age-related macular degeneration; PNV, pachychoroid neovasculopathy; PCV, polypoidal choroidal vasculopathy; DA nAMD, drusen-associated neovascular age-related macular degeneration; SD, standard deviation; PVD, posterior vitreous detachment; CRT, central retinal thickness; SFCT, subfoveal choroidal thickness; GLD, greatest linear dimension; CNV, choroidal neovascularization; SRF, subretinal fluid; IRF, intraretinal fluid.
*The Kruskal–Wallis test was used for analyses among the nAMD subtypes.
**The Mann–Whitney U-test was used for analyses between all nAMD and controls.